TY - JOUR
T1 - Full Robotic Distal Pancreatectomy
T2 - Safety and Feasibility Analysis of a Multicenter Cohort of 236 Patients
AU - Alfieri, Sergio
AU - Boggi, Ugo
AU - Butturini, Giovanni
AU - Pietrabissa, Andrea
AU - Morelli, Luca
AU - Di Sebastiano, Pierluigi
AU - Vistoli, Fabio
AU - Damoli, Isacco
AU - Peri, Andrea
AU - Lapergola, Alfonso
AU - Fiorillo, Claudio
AU - Panaccio, Paolo
AU - Pugliese, Luigi
AU - Ramera, Marco
AU - De Lio, Nelide
AU - Di Franco, Gregorio
AU - Rosa, Fausto
AU - Menghi, Roberta
AU - Doglietto, Giovanni Battista
AU - Quero, Giuseppe
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction. Despite the widespread use of the robotic technology, only a few studies with small sample sizes report its application to pancreatic diseases treatment. Our aim is to present the results of a multicenter study on the safety and feasibility of robot-assisted distal pancreatectomy (RDP). Materials and Methods. All RDPs for benign, borderline, and malignant diseases performed in 5 referral centers from 2008 to 2016 were included. Perioperative outcomes were evaluated. Results. Two hundred thirty-six patients were included. Spleen preservation was performed in 114 cases (48.3%). Operative time was 277.8 ± 93.6 minutes. Progressive improvement in operative time was observed over the study period. Conversion rate was 6.3%. Morbidity occurred in 102 cases (43.2%), mainly due to grade A fistulas. Reoperation was required in 10 patients. Postoperatively, 2 patients died of sepsis due to a grade C fistula. Hospital readmission was necessary in 11 cases. A R0 resection was always achieved, with a mean number of 16.2 ± 15 harvested lymph nodes. Conclusion. To our knowledge, this is one of the largest RDP series. Safety and feasibility including the low conversion rate, the high spleen preservation rate, the adequate operative time, and the acceptable morbidity and mortality rates confirm the validity of this technique. Appropriate oncological outcomes have been also obtained.
AB - Introduction. Despite the widespread use of the robotic technology, only a few studies with small sample sizes report its application to pancreatic diseases treatment. Our aim is to present the results of a multicenter study on the safety and feasibility of robot-assisted distal pancreatectomy (RDP). Materials and Methods. All RDPs for benign, borderline, and malignant diseases performed in 5 referral centers from 2008 to 2016 were included. Perioperative outcomes were evaluated. Results. Two hundred thirty-six patients were included. Spleen preservation was performed in 114 cases (48.3%). Operative time was 277.8 ± 93.6 minutes. Progressive improvement in operative time was observed over the study period. Conversion rate was 6.3%. Morbidity occurred in 102 cases (43.2%), mainly due to grade A fistulas. Reoperation was required in 10 patients. Postoperatively, 2 patients died of sepsis due to a grade C fistula. Hospital readmission was necessary in 11 cases. A R0 resection was always achieved, with a mean number of 16.2 ± 15 harvested lymph nodes. Conclusion. To our knowledge, this is one of the largest RDP series. Safety and feasibility including the low conversion rate, the high spleen preservation rate, the adequate operative time, and the acceptable morbidity and mortality rates confirm the validity of this technique. Appropriate oncological outcomes have been also obtained.
KW - hepatobiliary
KW - robotic surgery
KW - surgical oncology
UR - http://www.scopus.com/inward/record.url?scp=85070968830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070968830&partnerID=8YFLogxK
U2 - 10.1177/1553350619868112
DO - 10.1177/1553350619868112
M3 - Article
AN - SCOPUS:85070968830
JO - Surgical Innovation
JF - Surgical Innovation
SN - 1553-3506
ER -